Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Sexually Transmitted Diseases

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    October 2017
  1. LANDY R, Windridge P, Gillman MS, Sasieni PD, et al
    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31094.
    PubMed     Text format     Abstract available


  2. ZHU L, Sturgis EM, Zhang H, Lu Z, et al
    Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx.
    Int J Cancer. 2017;141:1355-1364.
    PubMed     Text format     Abstract available


    September 2017
  3. FABER MT, Sand FL, Albieri V, Norrild B, et al
    Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.
    Int J Cancer. 2017;141:1161-1169.
    PubMed     Text format     Abstract available


  4. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Text format     Abstract available


    August 2017
  5. RAKISLOVA N, Clavero O, Alemany L, Saco A, et al
    "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases".
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31006.
    PubMed     Text format     Abstract available


  6. VASILJEVIC N, Carter PD, Reuter C, Warman R, et al
    Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia.
    Int J Cancer. 2017;141:829-836.
    PubMed     Text format     Abstract available


  7. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Text format     Abstract available


  8. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    PubMed     Text format     Abstract available


    July 2017
  9. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Text format     Abstract available


  10. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
    Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
    PubMed     Text format     Abstract available


  11. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Text format     Abstract available


  12. CABEL L, Bidard FC, Servois V, Cacheux W, et al
    HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30863.
    PubMed     Text format     Abstract available


    June 2017
  13. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
    Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
    PubMed     Text format    


  14. HOLZINGER D, Wichmann G, Baboci L, Michel A, et al
    Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2017;140:2748-2757.
    PubMed     Text format     Abstract available


    May 2017
  15. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
    Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
    Int J Cancer. 2017;140:2212-2219.
    PubMed     Text format     Abstract available


  16. LOPES RDVC, Teixeira JA, Marchioni D, Villa LL, et al
    Dietary intake of selected nutrients and persistence of HPV infection in men.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30772.
    PubMed     Text format     Abstract available


  17. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
    PubMed     Text format    


  18. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Text format     Abstract available


  19. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
    Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
    Int J Cancer. 2017;140:2092-2100.
    PubMed     Text format     Abstract available


    April 2017
  20. RYSER M, Guignard A, Taylor S
    Letter to the Editor in response to Herweijer E., Sundstrom K., Ploner A., Uhnoo I., Sparen P. and Arnheim-Dahlstrom L. (2016), Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30753.
    PubMed     Text format    


  21. FU XI L, Schiffman M, Ke Y, Hughes JP, et al
    Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
    Int J Cancer. 2017;140:1747-1756.
    PubMed     Text format     Abstract available


  22. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Text format     Abstract available


    March 2017
  23. GHEIT T, Anantharaman D, Holzinger D, Alemany L, et al
    Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India.
    Int J Cancer. 2017 Mar 29. doi: 10.1002/ijc.30712.
    PubMed     Text format     Abstract available


  24. CHEOL PARK G, Roh JL, Cho KJ, Seung Kim J, et al
    18 F-FDG PET/CT vs. human papillomavirus, p16 and Epstein-Barr virus detection in cervical metastatic lymph nodes for identifying primary tumors.
    Int J Cancer. 2017;140:1405-1412.
    PubMed     Text format     Abstract available


  25. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
    Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
    PubMed     Text format     Abstract available


  26. PRIGGE ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M, et al
    Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.
    Int J Cancer. 2017;140:1186-1198.
    PubMed     Text format     Abstract available


  27. SCHNELLE C, Whiteman DC, Porceddu SV, Panizza BJ, et al
    Past sexual behaviors and risks of oropharyngeal squamous cell carcinoma: a case-case comparison.
    Int J Cancer. 2017;140:1027-1034.
    PubMed     Text format     Abstract available


    February 2017
  28. JEHANNIN-LIGIER K, Belot A, Guizard AV, Bossard N, et al
    Incidence Trends for Potentially Human Papilloma Virus-Related and -Unrelated Head and Neck Cancers in France using Population-based Cancer Registries Data: 1980-2012.
    Int J Cancer. 2017 Feb 6. doi: 10.1002/ijc.30631.
    PubMed     Text format     Abstract available


  29. LIEDERBACH E, Kyrillos A, Wang CH, Liu JC, et al
    The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma.
    Int J Cancer. 2017;140:504-512.
    PubMed     Text format     Abstract available


    January 2017
  30. HOFFMAN SR, Le T, Lockhart A, Sanusi A, et al
    Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.
    Int J Cancer. 2017 Jan 25. doi: 10.1002/ijc.30623.
    PubMed     Text format    


  31. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
    Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
    PubMed     Text format     Abstract available


  32. MITTAL S, Basu P, Muwonge R, Banerjee D, et al
    Risk of high grade precancerous lesions and invasive cancers in high risk HPV positive women with normal cervix or CIN 1 at baseline - a population based cohort study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30609.
    PubMed     Text format     Abstract available


  33. ANANTHARAMAN D, Abedi-Ardekani B, Beachler DC, Gheit T, et al
    Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30608.
    PubMed     Text format     Abstract available


  34. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
    Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Int J Cancer. 2017;140:423-430.
    PubMed     Text format     Abstract available


    December 2016
  35. WENTZENSEN N, Arbyn M, Berkhof J, Bower M, et al
    Eurogin 2016 Roadmap: How HPV knowledge is changing screening practice.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30579.
    PubMed     Text format     Abstract available


  36. HATANO T, Sano D, Takahashi H, Hyakusoku H, et al
    Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30589.
    PubMed     Text format     Abstract available


  37. BOGANI G, Chiappa V, Martinelli F, Raspagliesi F, et al
    Type-Specific HPV Infection Correlates with Risk of Recurrence of Vulvar Intraepithelial Neoplasia Usual Type.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30585.
    PubMed     Text format    


  38. CHEN W, Molijn A, Enqi W, Zhang X, et al
    The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
    Int J Cancer. 2016;139:2687-2697.
    PubMed     Text format     Abstract available


  39. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
    To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
    PubMed     Text format     Abstract available


    November 2016
  40. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
    Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
    Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
    PubMed     Text format     Abstract available


  41. WAKEHAM K, Kavanagh K, Cuschieri K, Millan D, et al
    HPV status and favorable outcome in vulvar squamous cancer.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30523.
    PubMed     Text format     Abstract available


  42. FU TC, Carter JJ, Hughes JP, Feng Q, et al
    Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.
    Int J Cancer. 2016;139:2201-12.
    PubMed     Text format     Abstract available


  43. TAINIO K, Jakobsson M, Louvanto K, Kalliala I, et al
    Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management.
    Int J Cancer. 2016;139:2353-8.
    PubMed     Text format     Abstract available


    October 2016
  44. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
    Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
    PubMed     Text format     Abstract available


  45. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
    Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
    Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
    PubMed     Text format     Abstract available


    September 2016
  46. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
    HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
    Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
    PubMed     Text format     Abstract available


  47. SUDENGA SL, Nelson Torres B, Fulp WJ, Silva R, et al
    Country-Specific HPV-related Genital Disease Among Men Residing in Brazil, Mexico, and the United States: The HIM Study.
    Int J Cancer. 2016 Sep 28. doi: 10.1002/ijc.30452.
    PubMed     Text format     Abstract available


  48. KYRGIOU M, Kalliala I, Mitra A, Ng KY, et al
    Immediate referral to colposcopy vs. cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.
    Int J Cancer. 2016 Sep 7. doi: 10.1002/ijc.30419.
    PubMed     Text format     Abstract available


  49. XI LF, Schiffman M, Koutsky LA, Hughes JP, et al
    Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia.
    Int J Cancer. 2016;139:1098-105.
    PubMed     Text format     Abstract available


    August 2016
  50. SIMMS KT, Smith MA, Lew JB, Kitchener HC, et al
    Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
    Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30392.
    PubMed     Text format     Abstract available


  51. GARLAND SM, Paavonen J, Jaisamrarn U, Naud P, et al
    Prior human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomised controlled trial.
    Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30391.
    PubMed     Text format     Abstract available


  52. GARNAES E, Frederiksen K, Kiss K, Andersen L, et al
    Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study.
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30389.
    PubMed     Text format     Abstract available


  53. ISIDEAN SD, Mayrand MH, Ramanakumar AV, Gilbert L, et al
    Human Papillomavirus Testing versus Cytology in Primary Cervical Cancer Screening: End-of-Study and Extended Follow-Up Results from the Canadian Cervical Cancer Screening Trial (CCCaST).
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30385.
    PubMed     Text format     Abstract available


  54. SCHIFFMAN M, Hyun N, Raine-Bennett TR, Katki H, et al
    A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage.
    Int J Cancer. 2016 Aug 10. doi: 10.1002/ijc.30375.
    PubMed     Text format     Abstract available


  55. ZOU H, Tabrizi SN, Grulich AE, Hocking JS, et al
    Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men.
    Int J Cancer. 2016;139:639-46.
    PubMed     Text format     Abstract available


    July 2016
  56. GUO T, Gaykalova DA, Considine M, Wheelan S, et al
    Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2016;139:373-82.
    PubMed     Text format     Abstract available


  57. VON KNEBEL DOEBERITZ M
    The causal role of human papillomavirus infections in non-anogenital cancers. It's time to ask for the functional evidence.
    Int J Cancer. 2016;139:9-11.
    PubMed     Text format    


    June 2016
  58. BODELON C, Untereiner ME, Machiela MJ, Vinokurova S, et al
    Genomic characterization of viral integration sites in HPV-related cancers.
    Int J Cancer. 2016 Jun 25. doi: 10.1002/ijc.30243.
    PubMed     Text format     Abstract available


  59. DEPUYDT CE, Thys S, Beert J, Jonckheere J, et al
    Linear viral load increase of a single HPV-type in women with multiple HPV infections predicts progression to cervical cancer.
    Int J Cancer. 2016 Jun 24. doi: 10.1002/ijc.30238.
    PubMed     Text format     Abstract available


  60. ZHAO FH, Hu SY, Zhang Q, Zhang X, et al
    Risk assessment to guide cervical screening strategies in a large Chinese population.
    Int J Cancer. 2016;138:2639-47.
    PubMed     Text format     Abstract available


    May 2016
  61. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
    Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
    PubMed     Text format     Abstract available


  62. WAGNER S, Wittekindt C, Reuschenbach M, Hennig B, et al
    CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2016;138:2263-73.
    PubMed     Text format     Abstract available


    April 2016
  63. TANG A, Dadaglio G, Oberkampf M, Di Carlo S, et al
    B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer.
    Int J Cancer. 2016 Apr 30. doi: 10.1002/ijc.30169.
    PubMed     Text format     Abstract available


    March 2016
  64. FRANCESCHI S, Umulisa MC, Tshomo U, Gheit T, et al
    Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30092.
    PubMed     Text format     Abstract available


  65. EBISCH RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, et al
    The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30090.
    PubMed     Text format     Abstract available


    February 2016
  66. BROTHERTON JM, Jit M, Gravitt PE, Brisson M, et al
    Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30063.
    PubMed     Text format     Abstract available


  67. KINES RC, Cerio RJ, Roberts JN, Thompson CD, et al
    Human papillomavirus capsids preferentially bind and infect tumor cells.
    Int J Cancer. 2016;138:901-11.
    PubMed     Text format     Abstract available


  68. HERWEIJER E, Sundstrom K, Ploner A, Uhnoo I, et al
    Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2016 Feb 9. doi: 10.1002/ijc.30035.
    PubMed     Text format     Abstract available


  69. PETRY KU, Cox JT, Johnson K, Quint W, et al
    Evaluating HPV negative CIN2+ in the ATHENA trial.
    Int J Cancer. 2016 Feb 6. doi: 10.1002/ijc.30032.
    PubMed     Text format     Abstract available


  70. SULTANA F, English DR, Simpson JA, Drennan KT, et al
    Home-based HPV self-sampling improves participation by never- and under-screened women: Results from a large randomised trial (iPap) in Australia.
    Int J Cancer. 2016 Feb 6. doi: 10.1002/ijc.30031.
    PubMed     Text format     Abstract available


  71. BHATIA R, Kavanagh K, Cubie H, Serrano I, et al
    Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.
    Int J Cancer. 2016 Feb 4. doi: 10.1002/ijc.30030.
    PubMed     Text format     Abstract available


  72. WANG HM, Cheng NM, Lee LY, Fang YH, et al
    Heterogeneity of (18)F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma.
    Int J Cancer. 2016;138:731-8.
    PubMed     Text format     Abstract available


    January 2016
  73. LORINCZ AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, et al
    Validation of a DNA methylation HPV triage classifier in a screening sample.
    Int J Cancer. 2016 Jan 20. doi: 10.1002/ijc.30008.
    PubMed     Text format     Abstract available


  74. MOLIJN A, Jenkins D, Chen W, Zhang X, et al
    The complex relationship between human papillomavirus and cervical adenocarcinoma.
    Int J Cancer. 2016;138:409-16.
    PubMed     Text format     Abstract available


  75. VOJTECHOVA Z, Sabol I, Salakova M, Turek L, et al
    Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis.
    Int J Cancer. 2016;138:386-95.
    PubMed     Text format     Abstract available


  76. STENSEN S, Kjaer SK, Jensen SM, Frederiksen K, et al
    Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.
    Int J Cancer. 2016;138:361-8.
    PubMed     Text format     Abstract available


  77. VAN BAARS R, van der Marel J, Snijders PJ, Rodriquez-Manfredi A, et al
    CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies.
    Int J Cancer. 2016;138:463-71.
    PubMed     Text format     Abstract available


  78. WANGSA D, Chowdhury SA, Ryott M, Gertz EM, et al
    Phylogenetic analysis of multiple FISH markers in oral tongue squamous cell carcinoma suggests that a diverse distribution of copy number changes is associated with poor prognosis.
    Int J Cancer. 2016;138:98-109.
    PubMed     Text format     Abstract available


    December 2015
  79. SKINNER SR, Wheeler CM, Romanowski B, Castellsague X, et al
    Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29971.
    PubMed     Text format     Abstract available


  80. FRANCESCHI S, Combes JD, Dalstein V, Caudroy S, et al
    Deep brush-based cytology in tonsils resected for benign diseases.
    Int J Cancer. 2015;137:2994-9.
    PubMed     Text format     Abstract available


  81. HOLL K, Nowakowski AM, Powell N, McCluggage WG, et al
    Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.
    Int J Cancer. 2015;137:2858-68.
    PubMed     Text format     Abstract available


  82. HAMMER A, Rositch A, Qeadan F, Gravitt PE, et al
    Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis.
    Int J Cancer. 2015 Dec 13. doi: 10.1002/ijc.29959.
    PubMed     Text format     Abstract available


    November 2015
  83. ZHANG F, Sturgis EM, Sun Y, Zhang Y, et al
    Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy.
    Int J Cancer. 2015;137:2454-61.
    PubMed     Text format     Abstract available


  84. FU TC, Fu Xi L, Hulbert A, Hughes JP, et al
    Short-term natural history of high-risk human papillomavirus infection in mid-adult women sampled monthly.
    Int J Cancer. 2015;137:2432-42.
    PubMed     Text format     Abstract available


  85. REICH O, Regauer S
    Two major pathways of recurrent high-grade squamous intraepithelial lesions of the cervix.
    Int J Cancer. 2015;137:2520-1.
    PubMed     Text format    


  86. HERFS M, Crum CP
    Response to "Two major pathways of recurrent high-grade squamous intraepithelial lesions of the cervix".
    Int J Cancer. 2015;137:2522-3.
    PubMed     Text format    


  87. CLIFFORD GM, Franceschi S, Keiser O, Schoni-Affolter F, et al
    Immunodeficiency and the risk of cervical intra-epithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV Cohort Study.
    Int J Cancer. 2015 Nov 4. doi: 10.1002/ijc.29913.
    PubMed     Text format     Abstract available


  88. HALEC G, Schmitt M, Egger S, Abnet CC, et al
    Mucosal Alpha-Papillomaviruses are not associated with Esophageal Squamous Cell Carcinomas: Lack of Mechanistic Evidence from South Africa, China and Iran and from a World-Wide Meta-Analysis.
    Int J Cancer. 2015 Nov 3. doi: 10.1002/ijc.29911.
    PubMed     Text format     Abstract available


    September 2015
  89. VALDEZ M, Jeronimo J, Bansil P, Qiao YL, et al
    Effectiveness of novel, lower-cost molecular human papillomavirus-based tests for cervical cancer screening in rural China.
    Int J Cancer. 2015 Sep 30. doi: 10.1002/ijc.29877.
    PubMed     Text format     Abstract available


  90. ZHANG R, Shen C, Zhao L, Wang J, et al
    Dysregulation of host cellular genes targeted by HPV integration contributes to HPV related cervical carcinogenesis.
    Int J Cancer. 2015 Sep 29. doi: 10.1002/ijc.29872.
    PubMed     Text format     Abstract available


    August 2015
  91. LUTTMER R, De Strooper LM, Berkhof J, Snijders PJ, et al
    Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
    Int J Cancer. 2015 Aug 28. doi: 10.1002/ijc.29824.
    PubMed     Text format     Abstract available


  92. LAPRISE C, Mathadil SA, Allison P, Abraham P, et al
    No role for human papillomavirus infection in oral cancers in a region in Southern India.
    Int J Cancer. 2015 Aug 28. doi: 10.1002/ijc.29827.
    PubMed     Text format     Abstract available


  93. CHUNG TK, Van Hummelen P, Chan PK, Cheung TH, et al
    Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.
    Int J Cancer. 2015;137:776-83.
    PubMed     Text format     Abstract available


    July 2015
  94. HEIDENREICH R, Jasny E, Kowalczyk A, Lutz J, et al
    A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
    Int J Cancer. 2015;137:372-84.
    PubMed     Text format     Abstract available


  95. BALERMPAS P, Rodel F, Rodel C, Krause M, et al
    CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Int J Cancer. 2015 Jul 14. doi: 10.1002/ijc.29683.
    PubMed     Text format     Abstract available


  96. GOSVIG CF, Huusom LD, Andersen KK, Duun-Henriksen AK, et al
    Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization.
    Int J Cancer. 2015 Jul 2. doi: 10.1002/ijc.29673.
    PubMed     Text format     Abstract available


  97. THOMSEN LT, Frederiksen K, Munk C, Junge J, et al
    Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Int J Cancer. 2015;137:193-203.
    PubMed     Text format     Abstract available


  98. RANIERI D, Belleudi F, Magenta A, Torrisi MR, et al
    HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition.
    Int J Cancer. 2015;137:61-72.
    PubMed     Text format     Abstract available


    June 2015
  99. WICHMANN G, Rosolowski M, Krohn K, Kreuz M, et al
    The role of HPV RNA transcription, immune response- related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Int J Cancer. 2015 Jun 20. doi: 10.1002/ijc.29649.
    PubMed     Text format     Abstract available


  100. CUZICK J, Myers O, Hunt WC, Saslow D, et al
    Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.
    Int J Cancer. 2015;136:2854-63.
    PubMed     Text format     Abstract available


  101. HOLLOWAY A, Simmonds M, Azad A, Fox JL, et al
    Resistance to UV-induced apoptosis by beta-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase.
    Int J Cancer. 2015;136:2831-43.
    PubMed     Text format     Abstract available


  102. BERGERON C, Ronco G, Reuschenbach M, Wentzensen N, et al
    The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments.
    Int J Cancer. 2015;136:2741-51.
    PubMed     Text format     Abstract available


    May 2015
  103. CAMPOS NG, Castle PE, Wright TC, Kim JJ, et al
    Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
    Int J Cancer. 2015 May 5. doi: 10.1002/ijc.29594.
    PubMed     Text format     Abstract available


    April 2015
  104. LONNBERG S, Hansen BT, Haldorsen T, Campbell S, et al
    Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway.
    Int J Cancer. 2015 Apr 1. doi: 10.1002/ijc.29541.
    PubMed     Text format     Abstract available


    November 2014
  105. KLINGHAMMER K, Raguse JD, Plath T, Albers AE, et al
    A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29344.
    PubMed     Text format     Abstract available


  106. HWANG TZ, Hsiao JR, Tsai CR, Chang JS, et al
    Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009.
    Int J Cancer. 2014 Nov 14. doi: 10.1002/ijc.29330.
    PubMed     Text format     Abstract available


    September 2014
  107. CHEN H, Chen XZ, Waterboer T, Castro FA, et al
    Viral infections and colorectal cancer: A systematic review of epidemiological studies.
    Int J Cancer. 2014 Sep 4. doi: 10.1002/ijc.29180.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: